All In Biotech

Drug Trial Radar · NCT06581575

A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine

A Phase 2, Randomized, Triple-Blinded, Active-Controlled Study to Assess the Safety and Immunogenicity of an Investigational Herpes Zoster (HZ) Vaccine, JCXH-105, in Healthy Subjects ≥ 50 Years of Age

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 467 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

467

Actual

Start

Oct 16, 2024

Primary completion

Feb 19, 2026

Study completion Mar 2027

Sponsor

Lead sponsor
Immorna Biotherapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Tigermed Consulting Co., Ltd
First posted
Sep 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to assess the safety and immunogenicity of an srRNA-based vaccine, JCXH-105, in the prevention of Herpes Zoster (Shingles). Subjects will be randomized to receive either JCXH-105 or Shingrix.

Conditions

  • Herpes Zoster (HZ)
  • Infectious Diseases
  • Shingles

Interventions

  • JCXH-105Biological

    IM injection

  • ShingrixBiological

    IM injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SAE FrequencyTime frame: Day 1 - Day 241 (Week 34)
  2. Solicited local reaction frequencyTime frame: Day 1 - Day 7 (After Dose 1), Day 1 - Day 7 (After Dose 2)
  3. Solicited systemic reaction frequencyTime frame: Day 1 - Day 7 (After Dose 1), Day 1 - Day 7 (After Dose 2)
  4. AE FrequencyTime frame: Day 1 - Day 241 (Week 34)
  5. AESIs FrequencyTime frame: Day 1 - Day 241 (Week 34)
  6. Medically Attended AE FrequencyTime frame: Day 1 - Day 241 (Week 34)
  7. Immune-Mediated Adverse Events of Special Interest FrequencyTime frame: Day 1 - Day 241 (Week 34)
  8. gE-Specific CD4+ T cell Response RateTime frame: Day 1 - Day 89 (Week 13)

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Noble Clinical Research

    Tucson, Arizona

  • Long Beach Research Institute

    Long Beach, California

  • DM Clinical Research - Chicago

    Chicago, Illinois

  • Quality Clinical Research

    Omaha, Nebraska

  • DM Clinical Research - New Jersey

    Jersey City, New Jersey

  • Delricht Research

    Charleston, South Carolina

  • Delricht Research

    Prosper, Texas

  • DM Clinical Research - Sugarland

    Sugar Land, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.